GLORIA PHARMA: Injectable multiple vitamins pass consistency evaluation

GLORIA PHARMA announced that its wholly-owned subsidiary, Pude Pharmaceutical, has received the approval notice for the supplementary application of injectable multivitamins issued by the National Medical Products Administration. This drug has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable multivitamins are suitable for adult patients and children over 11 years old, with sales expected to reach 1.916 billion yuan in urban public hospitals and county-level public medical institutions in China in 2024. Pude Pharmaceutical has invested approximately 3.6706 million yuan in the consistency evaluation work for this drug